Family · Pharmaceutical analytical standards
Ritonavir
An HIV protease inhibitor approved in the US in 1996; by slowing a cytochrome P450 liver enzyme it is also used as a booster for other drugs, for example with nirmatrelvir against COVID-19. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.
Did you know?In 1998, two years after approval, a new and far less soluble crystal form suddenly appeared, form II: it has been the textbook case of drug polymorphism ever since.
No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
